Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.
about
Risk based neoadjuvant chemotherapy in muscle invasive bladder cancerMuscle-invasive urothelial bladder cancer: an update on systemic therapyMultimodal management of muscle-invasive bladder cancerPerioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial CarcinomaElevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial CarcinomaSystemic, perioperative management of muscle-invasive bladder cancer and future horizons.Systemic therapy for bladder cancer finally comes into a new age.Systemic therapy in bladder cancerERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapySystemic therapy for bladder cancer - a medical oncologist's perspective.Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review.Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature.Adjuvant Chemotherapy Correlates with Improved Survival after Radical Cystectomy in Patients with pT3b (Macroscopic Perivesical Tissue Invasion) Bladder CancerThe ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer.The Role of Population-Based Observational Research in Bladder CancerNeoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.Prognostic features for quality of life after radical cystectomy and orthotopic neobladder.SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016).Oncologic outcomes obtained after neoadjuvant and adjuvant chemotherapy for the treatment of urothelial carcinomas of the upper urinary tract: a review.USANZ: Time-trends in use and impact on outcomes of perioperative chemotherapy in patients treated with radical cystectomy for urothelial bladder cancer.Adjuvant cisplatin-based combined chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of >1500 patients.Treatment of muscle invasive bladder cancer in the elderly: navigating the trade-offs of risk and benefit.Treatment of muscle-invasive bladder cancer: A systematic review.The safety and efficacy of gemcitabine for the treatment of bladder cancer.Chemotherapy for Muscle-Invasive Bladder Cancer.Improving Systemic Chemotherapy for Bladder Cancer.Dual targeting of heat shock proteins 90 and 70 promotes cell death and enhances the anticancer effect of chemotherapeutic agents in bladder cancerUpdates for the radiologist in non-muscle-invasive, muscle-invasive, and metastatic bladder cancer.Landmarks in the treatment of muscle-invasive bladder cancer.Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy.Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy.Delivering high-quality care to patients with muscle-invasive bladder cancer: Insights from routine practice in Ontario.Development and external validation of lymph node density cut-off points in prospective series of radical cystectomy and pelvic lymph node dissection.Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy.Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials.Prognostic and Predictive Value of O6-methylguanine Methyltransferase for Chemotherapy in Patients with Muscle-Invasive Bladder Cancer.The role of adjuvant chemotherapy in locally advanced bladder cancer.Peri-operative chemotherapy for muscle-invasive bladder cancer: status-quo in 2017.[Neoadjuvant, inductive or adjuvant chemotherapy of bladder cancer].
P2860
Q26773664-89285575-712D-4BC1-B10A-8CFC1D9163FEQ26775780-E810F13E-4887-4B38-B682-9AD90C491393Q27011624-48B58F27-995E-4028-800B-406FE287D34EQ27024948-E98F5E87-39F3-4AC5-ABF9-D7526B79EF38Q28084715-C176B9B6-34B9-49A9-AD06-A6BB2BF10159Q30240816-EC975745-EE7B-4460-AF13-845F78C0666EQ30249047-AC4C7F7D-182B-4B60-89C3-8996B7C89BAAQ33578564-7D343EBE-A3A8-491E-A5A6-83D930074F10Q34278209-35E71F71-B0B6-4451-8C33-DE0134F336F4Q34516731-DB5809E2-A949-44DA-9799-52FED319F1A0Q34993621-3629A76C-68EE-48A8-8A0F-A234AAFAD965Q35180823-E288B497-E805-4E6E-BA8D-52C162685F43Q35856850-4DE622DE-B562-44A6-94C3-2C20C5FE050DQ35911159-7D7F589D-6839-4FD5-8B75-A3BBA37EE40DQ37053750-3CFAEB7D-1A8D-4D0D-A778-7317F593A622Q37128756-05A2347B-D677-44F3-B1B4-298BDACED1BCQ37426972-17B6109C-AA12-487C-B1E9-FAE014D36FE6Q37475193-0107F1A6-8A7F-43A0-894A-9F4A68AEDC31Q38051010-B8642DCB-4651-4DDA-94BC-6356B2BB842DQ38152780-0365A05F-76AC-447C-990E-98DD373EDC59Q38218163-4540198C-5AB0-4389-868E-760EE77474E4Q38615547-B759216F-C3C4-448B-81A1-7F42CFCB3632Q38698579-702E7DD0-4706-4CF9-BBF2-EDD4461A4FD6Q38701535-6519A75A-5C04-4CAF-A277-14F9E92D9081Q38711504-DE2BBA39-7918-4AC6-97B8-9A55AFDA6EEFQ38777610-CE02A7F0-CD3A-46AB-BC55-62C7D7CF6837Q39005742-ADDD9AF0-8154-44E7-8F34-8F0DC9744841Q39350373-7726680E-9AEE-4ABF-918D-B630BE0EFB42Q39413207-32B3722D-AAA4-4CB3-B890-C7DE18C743F4Q39855461-E6E933AC-B902-4C9B-8DC5-50DBEF1C28D0Q41647263-17FAC28A-064A-4F80-9B66-3EACDE1BB6D2Q42970925-82BB5C09-281C-4FE5-93D3-018FA06B1D38Q44042378-8759108C-3AC4-4591-8BE4-B3C2C09352BCQ45083997-1092A76C-C837-499C-8280-05488FE139ECQ47137922-74851521-9B00-4230-8ED4-FB84F673A060Q47223305-65C3004D-CCA5-4EEC-BB48-158DD6149399Q47332651-94AA690D-7A95-4D04-B110-F5BA30F38D5DQ49526759-F943B312-BC74-4CF9-9856-2701B576077BQ54652590-CFBD590A-36DB-4F95-AF49-7D08BFB60F65
P2860
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Adjuvant chemotherapy with cis ...... r, randomized phase III trial.
@ast
Adjuvant chemotherapy with cis ...... r, randomized phase III trial.
@en
type
label
Adjuvant chemotherapy with cis ...... r, randomized phase III trial.
@ast
Adjuvant chemotherapy with cis ...... r, randomized phase III trial.
@en
prefLabel
Adjuvant chemotherapy with cis ...... r, randomized phase III trial.
@ast
Adjuvant chemotherapy with cis ...... r, randomized phase III trial.
@en
P2093
P2860
P921
P356
P1433
P1476
Adjuvant chemotherapy with cis ...... r, randomized phase III trial.
@en
P2093
A Rubagotti
B Massidda
C F Pollera
E M Ruggeri
F Boccardo
F Cognetti
Study Group
P2860
P304
P356
10.1093/ANNONC/MDR354
P577
2011-08-22T00:00:00Z